Doubt it was £400K in the bank really, as I believe he was running a short, so would have had to buy the stock back to close.
Classic short.
Ramp to get the price up on the sell side.
Deramp to try and buy back cheaper.
Screen shots to confuse, complaining his sells were printed as buys and lots of noise before and after to try and camouflage.
Parm,
Da was short imo.
Simple as that.
Showed his large sales on an HL screen shot from yesterday.
Claimed his sales incorrectly came through as buys today on LSE and showed a screen shot.
Which was a lie, I believe they were buys.
Classic short.
Definition for newbies:-
Short selling is a fairly simple concept—an investor borrows a stock, sells the stock, and then buys the stock back to return it to the lender.
The noise was just there to confuse.
I believe his butler has been very busy posting as well today ;)
Speranza,
People have quoted all sorts of sources, on here, for the register.
That doesn't mean to say everyone would be happy with that.
When looking at multisource data, from an IT perspective, you look for what we call the "golden source". This becomes even more important if you should be reporting to a financial regulator, where big fines can be imposed if the numbers are wrong/inaccurate.
Point being, it depends what you intend to do/action with that data. If it is for personal/internal use you might be happy with the inaccuracy.
Before blowing off publicly somewhere, imo, you should ensure the data is accurate, so you are presenting facts rather than interpretation.
Everyone here knew that the registers between the different platforms told a different story, even when everything looked "good".
A rather "fine" example, of a different note, is the feck up the government made with the Covid numbers and the loss of rows via an Excel spreadsheet.
I knew exactly why that had happened before they announced it.
Point being you need to use the right data for the right purpose.
I believe this should have been done by Da, in this instance.
"Some one can email MSP CORPORATE SERVICES LIMITED they are the company secretary. I believe they hold the correct share holder lists. And this would the definitive list."
Da, May I suggest that you do this rather than use and quote Bloomberg.
This is actually the golden source and will address any concerns you may have.
If you had done this, prior to selling and posting on here you would not have faced the flack you are now getting on here.
Who says Bloombergs the golden source anyway?
It's only as good as what is entered/imported into it.
It's a shame that my days working with investment banks are over, otherwise I would be able to check and confirm.
Antofelli,
Please back up and validate this statement for me please?
Or is this just general bitterness on your part?
What is your position here, short, bitter ex investor/victim of old management?
Or maybe part of the old management?
What is it?
"Pretty sure this has been the case for a while. They pay more for the drug but get the drug they want without spending billions sorting through the ****."
Yup, correct.
They also gain valuable expertise in that particular drug(s) and a shortcut to a quicker time to market.
Mer,
The other thing worth considering is the new business strategy with regards to VAL.
If you want to set yourself up as an overseer in bringing smaller pharma/biotechs to market, going forward, wouldn't you want to prove the concept, to the industry, with some of your own products first?
I have read that the pharma big boys general future strategy is acquisitions as gaining the right talent and managing the delivery of new drugs, inhouse, is proving difficult, ineffective and relatively expensive.
"For me this was the most valuable part was this - Evaluation of VAL301 by a potential partner nearing conclusion"
The other interesting thought, to me at least, is a document of this size will have taken a fair while to create.
Therefore, I can only assume that the Japanese pharma conclusions and subsequent announcement may be closer than previously thought.
All IMO.
GLA.
Agreed Daza,
Communications are key.
Once the ML is approved this should be communicated by an RNS right away, detailing that fact and next steps.
GLA.
I'm sure Suzy knows more about progress.
As I said very understated with comms, as scientists usually, rightfully, are, hence why I picked up on it right away.
Really quite positive IMO.
GLA.
antofelli,
I thought the document, itself, was very good and well put together, that is my main point.
They have just launched a new website, so why not have some more good content to put on it.
Yes, it might cost a few quid, but often these things pay for themselves in the long run.
I don't know your background here, but imo the new BOD have delivered quite a bit since they took over including cash in the bank.
That makes me happy to be invested here, it really is as simple as that.
"tweet tweet"
Guessing your new to technology?
"The key words are 'Marketing Communication' - if this is such a good investment why are Valirx paying a third party to write a report to encourage people to buy their shares?"
Nomlungu,
Congratulations!
You have just won the stupidest forum post of the week award.
Its called promotion, if the companies where you are invested, obviously not this one, don't do it then I guess the won't very successful.
Very good document and pitched at a good level, but I doubt you have actually read it.
Link to note https://twitter.com/DillySuzy/status/1324299347111063552?s=09
Interesting that it states that VAL 301s evaluation by the Japanese pharma is "nearing conclusion".
Dont think I've seen that stated before. Suzy seems to understate things, which I like, so I'm guessing before end of year.
It might be we get full 201 results and 301 news next.
Thanks Daz.
Will be interesting to see whether one, or both, of these gets their license soon.
"How can you buy just 1 share? 212 is £1 min value. Is there another with an even lower min value?"
Traders working for a financial organisation or trading house/broker can do this.